BAY 43-9006 inhibition of oncogenic RET mutants (Q34565246)

3 August 2017

BAY 43-9006 inhibition of oncogenic RET mutants (English)

1 reference

3 August 2017

Francesca Carlomagno

1

1 reference

3 August 2017

Suresh Anaganti

2

1 reference

3 August 2017

Teresa Guida

3

1 reference

3 August 2017

Giuliana Salvatore

4

1 reference

3 August 2017

Giancarlo Troncone

5

1 reference

3 August 2017

Scott M Wilhelm

6

1 reference

3 August 2017

Massimo Santoro

7

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Journal of the National Cancer Institute

3 August 2017

1 reference

3 August 2017

98

1 reference

3 August 2017

5

1 reference

3 August 2017

326-334

1 reference

Minireview: RET: normal and abnormal functions

3 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Molecular genetics of multiple endocrine neoplasia types 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Evolving strategies for targeted cancer therapy--past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

21 January 2018

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Early Malignant Progression of Hereditary Medullary Thyroid Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Strategies to overcome resistance to targeted protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Discovery of a novel Raf kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Targeting oncogene dependence and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

SRCircumventing imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ069

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJJ069

1 reference

3 August 2017

1 reference